112 related articles for article (PubMed ID: 31966511)
1. MLF1IP promotes cells proliferation and apoptosis by regulating CyclinD1 in breast cancer.
Yang F; Wang YH; Dong SY; Chen CZ; Huang DP
Int J Clin Exp Pathol; 2017; 10(12):11554-11562. PubMed ID: 31966511
[TBL] [Abstract][Full Text] [Related]
2. MLF1IP is correlated with progression and prognosis in luminal breast cancer.
Huang DP; Luo RC
Biochem Biophys Res Commun; 2016 Sep; 477(4):923-926. PubMed ID: 27378428
[TBL] [Abstract][Full Text] [Related]
3. MLF1 interacting protein: a potential gene therapy target for human prostate cancer?
Zhang L; Ji G; Shao Y; Qiao S; Jing Y; Qin R; Sun H; Shao C
Med Oncol; 2015 Feb; 32(2):454. PubMed ID: 25572810
[TBL] [Abstract][Full Text] [Related]
4. MLF1IP promotes normal erythroid proliferation and is involved in the pathogenesis of polycythemia vera.
Feng G; Zhang T; Liu J; Ma X; Li B; Yang L; Zhang Y; Xu Z; Qin T; Zhou J; Huang G; Shi L; Xiao Z
FEBS Lett; 2017 Mar; 591(5):760-773. PubMed ID: 28173615
[TBL] [Abstract][Full Text] [Related]
5. Regulation of myeloid leukemia factor-1 interacting protein (MLF1IP) expression in glioblastoma.
Hanissian SH; Teng B; Akbar U; Janjetovic Z; Zhou Q; Duntsch C; Robertson JH
Brain Res; 2005 Jun; 1047(1):56-64. PubMed ID: 15893739
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of the long non-coding RNA TUG1 is associated with cell proliferation, migration, and invasion in breast cancer.
Fan S; Yang Z; Ke Z; Huang K; Liu N; Fang X; Wang K
Biomed Pharmacother; 2017 Nov; 95():1636-1643. PubMed ID: 28950664
[TBL] [Abstract][Full Text] [Related]
7. miR-218 suppresses gastric cancer cell cycle progression through the CDK6/Cyclin D1/E2F1 axis in a feedback loop.
Deng M; Zeng C; Lu X; He X; Zhang R; Qiu Q; Zheng G; Jia X; Liu H; He Z
Cancer Lett; 2017 Sep; 403():175-185. PubMed ID: 28634044
[TBL] [Abstract][Full Text] [Related]
8. Rhomboid domain-containing protein 1 promotes breast cancer progression by regulating the p-Akt and CDK2 levels.
Zhang X; Zhao Y; Wang C; Ju H; Liu W; Zhang X; Miao S; Wang L; Sun Q; Song W
Cell Commun Signal; 2018 Oct; 16(1):65. PubMed ID: 30286765
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of CCAT2 promotes cell proliferation by repressing the P15 in breast cancer.
Deng X; Zhao Y; Wu X; Song G
Biomed Pharmacother; 2017 Jul; 91():1160-1166. PubMed ID: 28531944
[TBL] [Abstract][Full Text] [Related]
10. A novel long non-coding RNA FGF14-AS2 is correlated with progression and prognosis in breast cancer.
Yang F; Liu YH; Dong SY; Ma RM; Bhandari A; Zhang XH; Wang OC
Biochem Biophys Res Commun; 2016 Feb; 470(3):479-483. PubMed ID: 26820525
[TBL] [Abstract][Full Text] [Related]
11. cDNA cloning and characterization of a novel gene encoding the MLF1-interacting protein MLF1IP.
Hanissian SH; Akbar U; Teng B; Janjetovic Z; Hoffmann A; Hitzler JK; Iscove N; Hamre K; Du X; Tong Y; Mukatira S; Robertson JH; Morris SW
Oncogene; 2004 Apr; 23(20):3700-7. PubMed ID: 15116101
[TBL] [Abstract][Full Text] [Related]
12. MLF1-interacting protein is mainly localized in nucleolus through N-terminal bipartite nuclear localization signal.
Suzuki H; Arakawa Y; Ito M; Saito S; Takeda N; Yamada H; Horiguchi-Yamada J
Anticancer Res; 2007; 27(3B):1423-30. PubMed ID: 17595757
[TBL] [Abstract][Full Text] [Related]
13. BTG1 inhibits breast cancer cell growth through induction of cell cycle arrest and apoptosis.
Zhu R; Zou ST; Wan JM; Li W; Li XL; Zhu W
Oncol Rep; 2013 Nov; 30(5):2137-44. PubMed ID: 23982470
[TBL] [Abstract][Full Text] [Related]
14. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of cyclinD1 predicts for poor prognosis in estrogen receptor-negative breast cancer patients.
Umekita Y; Ohi Y; Sagara Y; Yoshida H
Int J Cancer; 2002 Mar; 98(3):415-8. PubMed ID: 11920593
[TBL] [Abstract][Full Text] [Related]
16. PRMT2β, a C-terminal splice variant of PRMT2, inhibits the growth of breast cancer cells.
Zhong J; Chen YJ; Chen L; Shen YY; Zhang QH; Yang J; Cao RX; Zu XY; Wen GB
Oncol Rep; 2017 Aug; 38(2):1303-1311. PubMed ID: 28677794
[TBL] [Abstract][Full Text] [Related]
17. MiR-1301-3p inhibits human breast cancer cell proliferation by regulating cell cycle progression and apoptosis through directly targeting ICT1.
Peng X; Yan B; Shen Y
Breast Cancer; 2018 Nov; 25(6):742-752. PubMed ID: 29951881
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of E2F8 promotes cell proliferation and tumorigenicity in breast cancer by modulating G1/S phase transition.
Ye L; Guo L; He Z; Wang X; Lin C; Zhang X; Wu S; Bao Y; Yang Q; Song L; Lin H
Oncotarget; 2016 Apr; 7(17):23757-71. PubMed ID: 26992224
[TBL] [Abstract][Full Text] [Related]
19. RNA interference-mediated silencing of NANOG reduces cell proliferation and induces G0/G1 cell cycle arrest in breast cancer cells.
Han J; Zhang F; Yu M; Zhao P; Ji W; Zhang H; Wu B; Wang Y; Niu R
Cancer Lett; 2012 Aug; 321(1):80-8. PubMed ID: 22381696
[TBL] [Abstract][Full Text] [Related]
20. Sperm-associated antigen 9 (SPAG9) promotes the survival and tumor growth of triple-negative breast cancer cells.
Jagadish N; Gupta N; Agarwal S; Parashar D; Sharma A; Fatima R; Topno AP; Kumar V; Suri A
Tumour Biol; 2016 Oct; 37(10):13101-13110. PubMed ID: 27449044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
